Exjade had a market value of roughly $113 million and Jadenu had a market value of about $470 million for the most recent 12 months ended in September.
The FDA has approved three applications for first generics of Novartis’ Gilenya (fingolimod) capsules for relapsing forms of multiple sclerosis in adult patients.
Amneal has received the Food and Drug Administration’s clearance for three generics that it is introducing immediately, including the first generic of Carafate (sucralfate oral suspension).
Zejula is now the only, once-daily PARP inhibitor approved as monotherapy treatment for recurrent ovarian cancer beyond those with a BRCA mutation in both the recurrent maintenance and late-line treatment settings.
Hectorol injection single-dose vials and multidose vials brand and generics had a market value of approximately $138 million for the most recent 12 months ending in September 2019, according to IQVIA.
Arakoda, the first antimalarial product approved by the Food and Drug Administration for the prevention of malaria, is being made available at select pharmacies and wholesalers.
Alnylam’s Givlaari has been approved by the FDA to treat a genetic disorder the causes buildup of toxic porphyrin molecules, which are formed during the production of heme.
Public quality standards set forth by USP increased competition in the generic medicines market and reduced overall prescription drug costs by $11 billion in 2015 and 2016.
In detailed letters to 15 Medicaid program directors. NACDS called for action on policy recommendations designed to help prevent opioid abuse and addiction, while caring for those in pain.
Cardinal Health’s first-quarter revenue was $33.4 billion. Despite being 6% greater than revenue in the same quarter last year, it was accompanied by a 3% drop in profit.
With the FDA approval of Ziextenzo — a biosimilar of Neulasta — Sandoz is the first and only company to offer long- and short-acting filgrastim biosimilar treatment options.
